GMED Globus Medical Inc Class A

Globus Medical Schedules First Quarter Earnings Release and Conference Call

Globus Medical Schedules First Quarter Earnings Release and Conference Call

AUDUBON, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2026 after the market close on Thursday, May 7, 2026. A copy of the release will be available on the Globus Medical website at .

Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at .

To participate via telephone, please register in advance at this . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

The audio archive will be available after the call on the Investors page of the Globus Medical website.

About Globus Medical, Inc.

Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with, health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company”, “Globus”, “Globus Medical”, “we”, “us”, and “our” refers to Globus Medical, Inc.

Contact

Brian Kearns

Senior Vice President, Corporate Development and Investor Relations

(610) 930-1800



EN
16/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Globus Medical Inc Class A

 PRESS RELEASE

Globus Medical Schedules First Quarter Earnings Release and Conference...

Globus Medical Schedules First Quarter Earnings Release and Conference Call AUDUBON, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2026 after the market close on Thursday, May 7, 2026. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call li...

 PRESS RELEASE

Globus Medical Announces Board Departure

Globus Medical Announces Board Departure AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the company of his decision to step down from the Board of Directors effective immediately and will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026. “We are grateful for John’s many contributions, especially during the merger with NuVasive and his service on the Nominating and Governance Committee. While we will miss his ins...

 PRESS RELEASE

Globus Medical Reports Fourth Quarter and Full Year 2025 Results

Globus Medical Reports Fourth Quarter and Full Year 2025 Results AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.GAAP net income for ...

 PRESS RELEASE

Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Re...

Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2025 after the market close on Tuesday, February 24, 2026. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Parti...

 PRESS RELEASE

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year...

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company anticipates fourth quarter 2025 sales of approximately $823.2 million, an increase of 25.2 percent over the fourth quarter 2024 on an as-reported basis. Full year 2025 sales are expected to be approximately $2.936 billion, an increase of 16.5 percent over ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch